Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06427642
NA

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Sponsor: Shandong Qilu Stem Cells Engineering Co., Ltd.

View on ClinicalTrials.gov

Summary

Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.

Official title: Efficacy Evaluation of Umbilical Cord Blood-derived Mononuclear Cells in the Treatment of Refractory Neonatal Diseases

Key Details

Gender

All

Age Range

1 Day - 28 Days

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2022-04-01

Completion Date

2025-04-30

Last Updated

2024-05-24

Healthy Volunteers

No

Interventions

BIOLOGICAL

Mononuclear cells

UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation

DEVICE

Mild hypothermia therapy

Mild hypothermia therapy via hypothermia therapy apparatus

DEVICE

Breathing support technique

Breathing support via ventilator

PROCEDURE

Total parenteral nutrition

Liquid nutrition injected directly into the bloodstream

Locations (1)

Qilu Children's Hospital of Shandong University

Jinan, Shandong, China